立体定向体部放疗作为老年及医学上无法手术头颈癌患者的初治方案
本研究纳入66例既往未接受放疗且医学上不适合常规治疗的头颈癌患者,采用SBRT(35-40 Gy至肿瘤区、30 Gy至临床靶区,5次分割)作为初治。中位年龄80岁,1年局部控制率73%、总生存率64%,仅2例出现3级毒性。结论认为SBRT在这类患者中疗效可接受且毒性较低。
要点
- SBRT可用于医学上不适合常规治疗的老年头颈癌初治患者。
- 1年局部控制率73%、总生存率64%,3级毒性仅2例。
- SBRT可能提供高局部控制与生存且维持生活质量。
核心结论
- SBRT在既往未放疗且医学上不适合常规治疗的头颈癌患者中显示可接受的疗效和相对较低的毒性。
研究设计与样本
- 单臂研究,纳入66例医学上不适合常规治疗且既往未接受放疗的头颈癌患者,接受SBRT(35-40 Gy至大体肿瘤区、30 Gy至临床靶区,5次分割)。
主要发现
- 中位年龄80岁;1年局部控制率为73%,1年总生存率为64%。
- 2例患者出现3级毒性。
关键数值与推荐
- SBRT剂量方案:35-40 Gy至大体肿瘤区,30 Gy至临床靶区,共5次分割。
临床怎么用
- 对于老年或医学上无法手术、不适合常规根治性治疗的头颈癌患者,可考虑SBRT作为初始局部治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with head and neck cancer (HNC) who are not candidates for definitive treatment represent an increasing challenge, with limited data to guide management. Conventional local therapies such as surgery and chemoradiation can significantly impact quality of life (QoL). There has been limited data published using stereotactic body radiotherapy (SBRT) as primary treatment in previously unirradiated patients. We hypothesize that SBRT provides high rates of control while limiting toxicity. METHODS: A total of 66 medically unfit previously unirradiated patients with HNC were treated with SBRT, consisting of 35-40 Gy to gross tumor volume and 30 Gy to clinical target volume in five fractions. RESULTS: Median age was 80 years. Local control (LC) and overall survival (OS) at 1 year were 73% and 64%. Two patients experienced grade 3 toxicity. CONCLUSION: SBRT shows acceptable outcomes with relatively low toxicity in previously unirradiated patients with HNC who are medically unfit for conventional treatment. SBRT may provide an aggressive local therapy with high rates of LC and OS while maintaining QoL.
引用
- Gogineni E, Rana Z, Vempati P, et al. Stereotactic body radiotherapy as primary treatment for elderly and medically inoperable patients with head and neck cancer. Head Neck. 2020. PMID: 32691496. doi:10.1002/hed.26342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。